Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia
Description
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) MeSH
Hierarchy View
Subtype Terms (9)
Leukemia, Hairy Cell
88 drugs (61 approved, 27 experimental)
Leukemia, Lymphoid
134 drugs (81 approved, 53 experimental)
Leukemia, Mast-Cell
23 drugs (16 approved, 7 experimental)
Leukemia, Myeloid
76 drugs (47 approved, 29 experimental)
Leukemia, Plasma Cell
44 drugs (34 approved, 10 experimental)
Approved Indicated Drugs (8)
Phase 2 Indicated Drugs (188)
90Yttrium-labelled Anti-CD66 Monoclonal Antibody
adenovirus type-5 vectored covid-19 vaccine
allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
allogeneic natural killer cells
allogeneic t cell progenitors, cultured ex-vivo
anti-minor histocompatibility complex (miha) donor t-lymphocytes
autologous epstein-barr virus-specific cytotoxic t lymphocytes
autologous expanded mesenchymal stem cells oti-010
autologous hematopoietic stem cells
autologous umbilical cord blood
bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine
cd34 selected progenitor cells
cytomegalovirus-specific cytotoxic t cells
haplo-identical hematopoietic stem cells
hydroxychloroquine (plaquenil)
in vitro-treated peripheral blood stem cell
lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam)
muromonab cd3 (Orthoclone OKT3)
patient derived cd19 specific car t cells also expressing an egfrt
p.dom-wt1-37 dna vaccine and p.dom-wt1-126 dna vaccine
Phase 1 Indicated Drugs (149)
anti-cd19-car gamma-delta t cells
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous differentiated t-cells
autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells
cd34-tk75 transduced donor lymphocytes
cd40 ligand and il-2 gene modified autologous skin fibroblasts and tumor cells
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins
donor memory t cells that have been depleted of cd62l+
il-2 and human cd40 ligand plasmid gene modified autologous tumor cells
Other Experimental Indicated Drugs (16)
Organization Involved with Phase 4 Indications (107)
Associazione Italiana Ematologia Oncologia Pediatrica
Badalona Hospital Germans Trias i Pujol
Canadian Immunization Research Network
Chinese Academy of Medical Sciences
Danish Child Cancer Foundation
Developmental Therapeutics Consortium
East Valley Hematology and Oncology Medical Group
German Federal Ministry of Education and Research
Gruppo Italiano Malattie EMatologiche dell'Adulto
HOVON - Dutch Haemato-Oncology Association
Huazhong University of Science and Technology
Huizhou People's Central Hospital
Italian Association of Pediatric Hematology-Oncology
National University of Singapore
Nordic Society for Pediatric Hematology and Oncology
People's Liberation Army of China
Postgraduate Institute of Medical Education and Research
Programa Nacional de Cancer Infantil de Chile
Russian Academy of Medical Sciences
Organization Involved with Phase 3 Indications (367)
Aamu Pediatric Cancer Foundation
Accutest Research Laboratories (I) Pvt. Ltd.
Acreditar - Associação de Pais e Amigos das Crianças com Cancro
Albert Einstein Israelite Hospital
All India Institute of Medical Sciences
Arbeitsgemeinschaft medikamentoese Tumortherapie
Assistance Publique - Hôpitaux de Paris
Azienda Ospedaliera San Gerardo di Monza
Bangabandhu Sheikh Mujib Medical University
Beijing InnoCare Pharma Tech Co., Ltd.
Blood and Marrow Transplant Clinical Trials Network
Cancer and Leukemia Group B (CALGB)
Case Western Reserve University
Center for International Blood and Marrow Transplant Research
Central European Leukemia Study Group
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
Changzhou No.2 People's Hospital
Children's Cancer and Leukaemia Group
Children's National Medical Center
Christian Medical College, Vellore, India
CHU Haut-Leveque Pessac 33604 France
Cohen Children's Medical Center of New York
Cook Children's Medical Center
Cristália Produtos Químicos Farmacêuticos Ltda.
Cyclacel Pharmaceuticals, Inc.
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)
Dutch Childhood Oncology Group
Eastern Cooperative Oncology Group
European Working Group of MDS in Childhood
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
First People's Hospital of Chenzhou
French Innovative Leukemia Organisation
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Gottfried Wilhelm Leibniz Universität Hannover
Groupe d'etude et de travail sur les leucemies aigues promyelocytaires
Groupe Francophone des Myelodysplasies
Grupo Español de Leucemia Linfocítica Crónica (GELLC)
Grupo Português De Leucemias Pediátricas
Gruppo Italiano Trapianto di Midollo Osseo
Haemato Oncology Foundation for Adults in the Netherlands
Herbert Irving Comprehensive Cancer Center
Hoosier Cancer Research Network
Hospital Civil Juan I. Menchaca
Hospital de Pediatria Garrahan
Huai'an Second People's Hospital
Icahn School of Medicine at Mount Sinai
Instituto de Investigacion de Cancer de la Infancia y la Adolescencia
Instituto de Investigacion en Cancer de la Infancia y la Adolescencia
Instituto de Medicina Integral Professor Fernando Figueira
Japan Adult Leukemia Study Group
Justus Liebig University Giessen
Katholieke Universiteit Leuven
Maine Children's Cancer Program
Med. Klinik III, Klinikum Leverkusen gGmbH, Germany
National Cancer Institute, France
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of General Medical Sciences (NIGMS)
National Institute of Nursing Research (NINR)
National Institutes of Health (NIH)
National University of Malaysia
Nordic CLL Study Group (NCLLSG)
Oregon Health and Science University
Physicians, Innovations, Science for Children Fund
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Royal Marsden Hospital NHS Trust
San Jorge Children's Hospital, Puerto Rico
Shandong Lanjin Pharmaceuticals Co.,Ltd
Shanghai Ruijin Hospital North
Shengli Oilfield Central Hospital
Shijiazhuang Pharma Group (CSPC)
Societe Francaise Oncologie Pediatrique
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
The Canadian Blood and Marrow Transplant Group
The Christie NHS Foundation Trust
The First People's Hospital of Lianyungang
The Israeli CLL Study Group (ICLLSG)
The Leukemia and Lymphoma Society
The Second People's Hospital of Huai'an
The University of Texas, Dallas
Universitaetsklinikum Schleswig-Holstein
University of California, Irvine
University of California, Los Angeles
University of Medicine and Dentistry of New Jersey
University of Roma La Sapienza
University of Rome Tor Vergata
University of Texas, San Antonio
University of Western Australia
Vall d'Hebron Institute of Research, Galatea Clinic
Virginia Commonwealth University
Vita-Salute University of Milano. Italy
Willamette Valley Cancer Institute
Organization Involved with Phase 2 Indications (509)
Academic and Community Cancer Research United
Advancell - Advanced In Vitro Cell Technologies, S.A.
Associazione Italiana per la Ricerca sul Cancro
Australasian Leukaemia and Lymphoma Group
Azienda Ospedaliera Antonio Cardarelli
Azienda Ospedaliera Ospedale Civile di Legnano
Azienda Ospedaliera Universitaria Senese
Azienda Osperdaliera Vincenzo Cervello Divisione
Bambino Gesù Hospital and Research Institute
Betta Pharmaceuticals Co.,Ltd.
Bio-Cancer Treatment International Limited
BioMed Valley Discoveries, Inc
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
Central Maryland Oncology Center
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Chao Family Comprehensive Cancer Center
Children's Hospital Los Angeles
Chinese University of Hong Kong
Chongqing Precision Biotech Co., Ltd
Chronic Lymphocytic Leukemia Research Consortium
City of Hope National Medical Center
Clinica Universidad de Navarra
Colorado Blood Cancer Institute
Complessa di Ematologia and Dir Departmento
CZECRIN - Czech Clinical Research Infrastructure Network
Department of Health and Human Services
Department of Health, United Kingdom
Epidemiological and Clinical Research Information Network
European Group for Blood and Marrow Transplantation
Federal University of Health Science of Porto Alegre
Federal University of Rio de Janeiro
Federal University of Rio Grande do Sul
First People's Hospital of Foshan
Fondazione Italiana Diabete Onlus
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Froedtert Memorial Lutheran Hospital
Fundacao Hospital Amaral Carvalho
Fundación Teófilo Hernando, Spain
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Grupo Cooperativo de Hemopatías Malignas
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Guangdong Pharmaceutical University
Hackensack University Medical Center
Hannover Clinical Trial Center GmbH
Henan University of Traditional Chinese Medicine
Hoag Memorial Hospital Presbyterian
HOANNJ-Carol G. Simon Cancer Center
Hôpital Mignot, Versailles Paris
Hopital Rene Huguenin_Intitut Curie_Paris
Hospital de Clinicias da UICAMP
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hospital Nossa Senhora da Conceicao
Hospital San Pedro de Alcantara
Hospital Santa Marcelina, Sao Paulo, Brasil
Hospital Universitario Ramon y Cajal
Infinity Pharmaceuticals, Inc.
Innovative Therapies For Children with Cancer Consortium
Innovent Biologics (Suzhou) Co. Ltd.
Institut de Cancérologie de la Loire (ICLN)
Institut de Cancerologie de l'Ouest Paul Papin
Institute of Hematology and Blood Transfusion, Czech Republic
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Instituto Mexicano del Seguro Social
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
IRCCS Centro di Riferimento Oncologico della Basilicata
Istituti Ospitalieri di Cremona
Istituto Nazionale per lo Studio e la Cura dei Tumori
Istitutp di Ematologia ed Oncologia Medica
James Graham Brown Cancer Center
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Korea Research Institute of Bioscience and Biotechnology
Korea Research Institute of Bioscience & Biotechnology
La Jolla Pharmaceutical Company
Liberty Hematology and Oncology
Medical University of South Carolina
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
National Center for Research Resources (NCRR)
National Comprehensive Cancer Network
National Hospital Organisation Nagoya Medical Centre
National Hospital Organization, Mito Medical Center
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Aging (NIA)
New Mexico Cancer Care Alliance
New York Presbyterian Hospital
North Central Cancer Treatment Group
North Shore Hospital, New Zealand
Norwegian University of Science and Technology
Ospedale S. Giovanni Bellinzona
Our Lady of Mercy Medical Center
Pavlov First Saint Petersburg State Medical University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Philipps University of Marburg
Presidio Ospedaliero Spedali Civili di Brescia
Rio de Janeiro Federal University
Rocky Mountain Cancer Centers - Denver Midtown
Santobono - Pausilipon Hospital
Second Military Medical University
Service Clinique des Maladies du Sang
service Hématologie Séniors Hôpital Saint Louis
Shanghai Children Medicine Center
Shanghai institute of Hematology
Shenzhen Geno-Immune Medical Institute
Shenzhen Institute for Innovation and Translational Medicine
Shimousa Hematology Study Group
Simcere Pharmaceutical Co., Ltd
Teaching Hospital Královské Vinohrady (FNKV)
Technical University of Denmark
Technical University of Munich
The Beijing Pregene Science and Technology Company, Ltd.
The First People's Hospital of Yunan Province
The Foundation Institute San Raffaele G. Giglio of Cefalù
The Korean Society of Blood and Marrow Transplantation
The Korean Society of Hematology
The Korean Society of Pediatric Hematology Oncology
The Lymphoma Academic Research Organisation
The Royal Bournemouth Hospital
The Scientific and Technological Research Council of Turkey
The Wayne D. Kuni and Joan E. Kuni Foundation
Tokyo Metropolitan Komagome Hospital
Universidad Autonoma de Madrid
Universidade Federal do Parana
Universita' Cattolica del Sacro Cuore
Universita Degli Studi La Sapeinza
Université catholique de Louvain
University Hospital Hradec Kralove
University Hospital of Mont-Godinne
University Hospital of North Norway
University of Alabama, Birmingham
University of British Columbia
University of California, Davis
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Illinois at Chicago
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Picardie Jules Verne
University of Southern California
University of Southern Denmark
U.O. di Ematologia- Ospedale dell'Angelo - Mestre
Organization Involved with Phase 1 Indications (204)
Acetylon Pharmaceuticals Incorporated
Aeon Therapeutics (Shanghai) Co., Ltd.
Alex's Lemonade Stand Foundation
Applied Physiology Research Center
Beijing Sanwater Biological Technology Co., Ltd.
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Bharath Hospital and Institute of Oncology
Big Ten Cancer Research Consortium
Boryung Pharmaceutical Company
Cantonal Hospital of St. Gallen
Cellular Biomedicine Group Ltd.
Children's National Research Institute
CLL Global Research Foundation
Damon Runyon Cancer Research Foundation
GCP-Service International Ltd. & Co. KG
Georgia Institute of Technology
Hamilton Health Sciences Corporation
Hebei Senlang Biotechnology Inc., Ltd.
Henan Hualong Biotechnology Company
High Impact Clinical Research Support Program
HonorHealth Research Institute
Innovative Clinical Research, Inc.
Institut de Recherche Clinique sur les Cancers et le Sang
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Laboratoire français de Fractionnement et de Biotechnologies
MingSight Pharmaceuticals Pty Limited
Nanjing Bioheng Biotech Co., Ltd.
Pediatric Brain Tumor Consortium
Pediatric Oncology Experimental Therapeutics Investigation Consortium
Pharmaceutical Research Associates, Inc. (PRA)
Shanghai Longyao Biotechnology Inc., Ltd.
Shenzhen immune gene therapy research institute
South Plains Oncology Consortium
Sunnybrook Health Sciences Centre
Sunshine Lake Pharma Co., Ltd.
Swiss Pediatric Oncology Group
Tehran University of Medical Science
Tianjin Mycure Medical Technology Co., Ltd
Translational Drug Development
Union Stem Cell & Gene Engineering Co.LTD
University of California, Berkeley
University of Maryland, College Park
University of Science and Technology of China
William Lawrence and Blanche Hughes Foundation
Wuhan Bio-Raid Biotechnology Co, Ltd. China
Organization Involved with Other Experimental Indications (30)
American Society of Clinical Oncology
Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Australian and New Zealand Children's Oncology Group
Children's Cancer Research Fund United States
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.